OBJECTIVES: Insulin-resistance syndrome and hyperinsulinaemia are linked with cardiovascular disease (CVD) in the obese population. In particular, cardiovascular risk is more frequent in central obesity and is associated with microalbuminuria (MA). MA and changes of glomerular permeability to proteins in obesity might be related with renal haemodynamic modi®cations (that is glomerular hyper®ltration). Since glucagon is physiologically involved in renal haemodynamic regulation, the purpose of this study was to examine whether changes of circulating glucagon levels might haemodynamically induce MA and proteinuria in patients with central obesity. SUBJECTS: Forty normotensive obese out-patients, 22 with central (CO group) and 18 with peripheral (PO group) body fat distribution and 11 healthy subjects. MEASUREMENTS:Serum insulin and glucagon concentrations (fasting and after oral glucose tolerance test (OGTT)) by radio immuno assay (RIA); glomerular ®ltration rate (GFR, isotopic); total clearances and urinary excretion rates of albumin (AER), IgG (IgGER) and a a1 microglobulin (computerized immunonephelometry). RESULTS: GFR and insulin concentrations (fasting and during OGTT) were higher in the CO than the PO group. Fasting glucagon concentrations were increased, and not physiologically suppressed during OGTT in patients with CO (fasting, P`0.05; OGTT 60 and 120 min, P`0.001 vs PO group). Moreover, glucagon concentrations were signi®cantly correlated with GFR in the CO group (fasting, r 0.49, P`0.05; 60 min after OGTT, r 0.58, P`0.01); whereas no correlations were found in the PO group. Higher AER (P`0.001), IgGER (P`0.001) and a1 microglobulin (P`0.05) urinary concentrations were found in patients with CO than in the PO group. CONCLUSIONS: The increase of serum glucagon concentrations may be associated with the enhancement of GFR in patients with central obesity. Glomerular hyper®ltration might in¯uence the development of MA and of proteinuria by means of a haemodynamic mechanism so contributing to increase the risk of renal microvascular complications and of CVD in central obesity.
Introduction
Hyperinsulinaemia and insulin-resistance syndrome (HRS) are associated with increased risk of cardiovascular disease (CVD) in the obese population. 1 ± 6 In particular, the increased prevalence of metabolic disorders and CVD is higher in subjects with obesity of the central type than in obese subjects with peripheral body fat distribution 7, 8 so suggesting central body fat topography as predictive for development of CVD and HRS in the obese population.
Experimental and clinical data have reported that hyperinsulinaemia was often associated with proteinuria and microalbuminuria (MA) revealing MA as a potential clinical marker of cardiovascular risk in obese as well as in non obese populations. 9, 10 Moreover, in our previous study MA was demonstrated in patients with central obesity and haemorheologic disorders 11 and was suggested to be dependent on glomerular haemodynamic alterations. 12 Since circulating glucagon and insulin concentrations have been involved in the regulation of glomerular ®ltration rate (GFR) and hence of renal haemodynamic function, 13 ± 18 a role of these factors in the development of abnormal GFR and MA may be suggested in obesity with central body fat distribution. Within this context, the present study was undertaken to evaluate GFR together with serum insulin and glucagon concentrations and urinary excretion of proteins (albumin, IgG and a1 microglobulin) in obese patients with central and peripheral body fat topography.
Materials and methods

Subjects
Our clinical investigations concerned three groups of subjects. After informed consent, 11 clinically healthy subjects, 18 normotensive patients with peripheral obesity (PO) and 22 normotensive patients with central obesity (CO) were included in the study. The clinical features of obese patients and of healthy subjects were summarized in Table 1 . Weight and height of healthy subjects and of obese patients were determined in the fasting state without shoes and clothes. Obesity was de®ned on the basis of body mass index (BMI) higher than 30.5 kgam 2 for men and 27.3 kgam 2 for women. 19 The ratio of waist to hip circumferences (WHR) was chosen as an index of body fat distribution. Anthropometric measurements were assessed to the nearest mm with a plastic tape, the subjects being in a standing position and breathing normally. Waist was determined at the smallest waist circumference, and the hip circumference measured at the level of the great trochanter. Central obesity was de®ned as occurring when WHR b 0.82 for women and WHR b 0.92 for men. 19 Exclusion criteria for obese patients included arterial hypertension, cardiovascular and renal diseases, smoking, diabetes mellitus, alcholism, intercurrent illness and clinical symptoms related to sleep apnea syndrome.
An oral glucose tolerance test (OGTT, 75 g orally) was performed in healthy subjects and in obese patients in order to evaluate the variations of circulating insulin and glucagon from fasting values. Measurements of serum insulin and glucagon were made 60 min and 120 min after glucose administration.
Methods
All the biochemical parameters (blood glucose, total and HDL-cholesterol and triglycerides) were determined by an automatic procedure (DASIT) Autoanalyzer, Cornaredo, Milano, Italy).
Serum insulin and glucagon concentrations were measured fasting and 60 min and 120 min after OGTT (75 g orally); a double antibody RIA was employed for both measurements (DPC, Los Angeles, CA, USA).
Glomerular ®ltration rate (GFR) was determined by using a single intravenous injection of 2 mCi of 99 mTc-DTPA; the measurements were normalized for a standard body surface area (BSA) of 1.73 m 2 . Urinary excretion rates of albumin (AER), igG (IgGER) and a1 microglobulin were determined within 48 h from sampling. 20 A 24 h urine collection in sterile cool containers (polystyrene tubes, Corning Inc. NY, USA) was obtained for each patient and subject, afterwards urine samples were centrifuged at 250 g at 18 C. Serum for albumin and IgG was drawn from sterile tubes (SST 3200 Vacutainer Hemogard, Becton Dickinson, Milano, Italy). Urinary and serum proteins were determined by fully automated computerized nephelometry (BNA, Behringwerke AG, Marburg, Germany). 20 Urinary albumin and IgG were expressed as dynamic excretion rate (mgamin), a1 microglobulin as mgaL. Serum and urinary measurements were also employed to determine the total clearance of proteins (Ux VaP) expressed in mLamin and normalized for a standard BSA of 1.73 m 2 . The ratio between IgG and albumin fractional clearances (fractional clearance total clearanceaGFR) was used to evaluate the selectivity index (SI).
Plasma.non-esteri®ed fatty acids (NEFA) were determined by a colorimetric micromethod.
Statistical analysis
Data are expressed as range and mean AE standard deviation. Differences among the groups were evaluated by one-way ANOVA followed by Scheffe's Ftest. Univariate correlation coef®cients (r) were used to evaluate the relationship between glucagon and GFR. Multiple regression analysis was performed to assess the relation of independent variables (metabolic parameters) with serum glucagon concentrations, GFR and AER as dependent variables. P`0.05 was considered as the threshold of statistical signi®cance (two-tailed). All analyses were run with the SPSSaPC V3.0 statistical package. Central obesity, renal hemodynamics and glucagon SB Solerte et al
Results Table 1 summarizes the clinical features of obese patients and of healthy subjects. All groups examined were comparable for sex, age and arterial blood pressure levels. Patients with central and peripheral obesity were also comparable for BMI, whereas WHR clearly distinguished the two groups of obese patients (CO central type; PO peripheral type). Figure 1 and 2 show the mean variations (s.d.) of fasting and after OGTT serum insulin and glucagon concentrations in the three groups of subjects. Increased insulin (fasting and 60, 120 min after OGTT) and fasting glucagon concentrations were found in patients with CO compared to patients with PO and to healthy subjects. Serum glucagon concentrations were signi®cantly reduced after OGTT in healthy subjects and in patients with PO (P`0.001 after 60 and 120 min), whereas serum glucagon concentrations were not suppressed after OGTT in patients with CO. Concerning insulin concentrations, the logarithmic transformation of the data con®rmed the same level of signi®cance (P`0.01 fasting and after 120 min; P`0.001 after 60 min) to the data expressed as non logarithmic (Figure 1) .
Signi®cantly higher plasma NEFA concentrations were demonstrated in patients with CO (0.70 AE 0.2 mmolaL) than in patients with PO (0.45AE 0.13 mmolaL, P`0.001) and in healthy subjects (0.40 AE 0.11 mmolaL, P`0.001). Figure 3 shows the mean variations (s.d.) of GFR in healthy subjects and in patients with PO and CO Higher GFR was demonstrated in patients with CO (128AE 18 mlamina1.73m 2 than in patients with PO (104AE 13 mlamina1.73 m 2 , P`0.05) and in healthy subjects (102AE 11 mlamina1.73 m 2 , P`0.05). Central obesity, renal hemodynamics and glucagon SB Solerte et al Figure 4 shows the correlations between glucagon concentrations (fasting and 60 min after OGTT) and GFR in patients with CO. Signi®cant correlations between glucagon (P`0.05 fasting and P`0.01 60 min after OGTT) and GFR were found in these patients. On the contrary, no signi®cant correlations were found in patients with PO (r 0.15 and r 0.09 respectively). Table 2 summarizes the total clearances and the urinary excretion rates of albumin (AER), IgG (IgGER) and a1 microglobulin and SI in healthy subjects and obese patients. Higher AER, IgGER and urinary a1 microglobulin levels were demonstrated in patients with CO than in patients with PO and in healthy subjects. The total clearances of albumin and IgG were also signi®cantly increased in patients with CO compared to the other two groups; whereas no change of SI was demonstrated when CO patients were compared to healthy subjects or to patients with PO. Table 3 summarizes multiple linear regression analysis among AER and GFR (as the dependent variables) and the metabolic parameters (as the independent variables) in patients with CO. A mild but signi®cant (P`0.05) correlation between plasma NEFA and GFR was found in this group of patients. On the contrary, no correlation among the other metabolic parameters, GFR or AER was demonstrated. Multiple linear regression analysis between glucagon concentrations (as dependent variables) and the metabolic parameters (as the independent variables) was also employed in patients with CO. The analysis reported that plasma NEFA concentrations were signi®cantly correlated with glucagon values (fasting values: r 0.490, P`0.05; 60 min after OGTT values: r 0.597, P`0.01); whereas no correlation among the other parameters and glucagon was demonstrated. In particular, fasting blood glucose, cholesterol (total and HDL), triglycerides and insulin concentrations had no in¯uence on the relationships observed when these factors were incorporated as independent variables (r within 0.050 and 0.203).
Discussion
Our study provides evidence that increased circulating glucagon concentrations are present in patients with central obesity, whereas patients with peripheral obesity had normal serum glucagon concentrations. Hence, as suggested in previous work, 11 hyperglucagonaemia might represent, together with hyperinsulinaemia and elevated plasma NEFA, a metabolic feature of central obesity. At present, less data are available on circulating glucagon concentrations in obesity and it is not clear whether glucagon can play a role in human obesity and related complications. Nevertheless, elevated pancreatic glucagon 21 and glucagon resistance 22 have been reported in humans and animals. Our data have demonstrated increased fasting glucagon concentrations, without suppression of circulating glucagon during OGTT, in obesity of the central type. Moreover, this increase was associated with elevated NEFA and glomerular ®ltration rate and with urinary protein loss.
The link between glucagon and several metabolic disorders of obese animals and humans has been reported in the literature. 11, 22, 23 Our data appear to be similar to those of Iannello et al 23 24 Moreover, a link between NEFA and glucagon was reported in obese subjects 11, 23 In the present study, normal fasting blood glucose values were found in patients with central obesity (4.42 AE 0.3 mmolaL vs 4.28AE 0.3 mmolaL of healthy subjects) and no correlations between blood glucose (fasting and after OGTT) and glucagon concentrations were found. Therefore, the defect of a cell function and of modulation of glucagon secretion would seem to be independent of blood glucose variations in our patients with obesity of central type. All these data indicate the need for further experimental and clinical investigations of glucagon concentrations in patients with obesity.
An intriguing possibility in this study concerns the role of glucagon in the development of renal haemodynamic alterations in patients with central obesity. Within this context, it has been long assumed that glucagon can regulate glomerular haemodynamic function by increasing GFR by means of speci®c mechanisms (that is: direct vasodilatory effects, increase of glomerular ®ltration surface area, reduced activity of the cAMP-dependent tubuloglomerular feed-back). 13 ± 15 In fact, glucagon concentrations were signi®cantly correlated with GFR in our patients with CO, indicating that circulating glucagon may contribute to increase GFR and to in¯uence renal haemodynamic function also in obese patients with central body fat distribution. The relationships were demonstrated with fasting values and with the persistance of increased concentrations during OGTT. Glomerular haemodynamics of CO patients could therefore be in¯uenced by changes of serum glucagon after carbohydrate intake and meals Although hyperinsulinaemia may have no effect on GFR regulation, 17 the hyperinsulinaemic pattern Central obesity, renal hemodynamics and glucagon SB Solerte et al found in patients with central obesity might contribute to sustain the increase of GFR in these patients. 16 Since hyperinsulinaemia can decrease glucagon concentrations during aeuglycaemic clamp, 25, 26 it is of a certain importance the observation that hyperglucagonaemia was evident in our patients with CO even in the presence of increased circulating insulin concentrations. The impact of central obesity on glucagon concentrations may therefore be independent of variations of insulin secretion suggesting a glucagon resistance syndrome amongst the metabolic characteristics of central obesity. Plasma NEFA concentrations are increased in our patients with central obesity and are correlated with circulating glucagon concentrations and with the increase of GFR. These data suggest that elevated serum glucagon values may play a role in the abnormal regulation of NEFA in patients with CO. Although the link between circulating glucagon and plasma NEFA concentrations remains controversial, 27 hypoglucagonaemia can suppress NEFA appearance while hyperglucagonaemia can stimulate NEFA appearance in healthy subjects. 28 Within this context, it is well known that glucagon is an important antagonist of insulin action of FFA metabolism and that glucagon can physiologically stimulate the synthesis and the release on FFA. 29, 30 Concerning the association found between glucagon and NEFA, our data appear to be similar to those reported in the literature for obese type 2 diabetic patients. 24 Moreover, since large fat cells per se can determine increased NEFA availability, 31, 32 body fat mass, the size and the topography of fat depots might give further support to explain the association found between glucagon and NEFA in patients with central obesity.
A relevant question arising from our study is whether glucagon and insulin abnormalities found in CO can haemodynamically in¯uence the permeability of the glomerular basement membrane (GBM) to serum proteins. 14 ± 18 This might have important pathophysiological consequences in obese patients, since the loss of proteins through the GBM is considered a marker of incipient vascular derangement and CVD. 33 ± 35 On the other hand, our previous study reported that body weight reduction can decrease urinary protein loss by improving renal haemodynamic function in obese patients with diabetes mellitus. 36 The present investigation demonstrates that the correlation between the increase of glucagon and GFR found in patients with CO is associated with a pathological increase of AER and IgGER and of the total clearance of these proteins. Therefore, a role for glucagon in transglomerular loss of proteins may be suggested in obesity of central type. In fact, hyperglucagonaemia and the other related haemodynamic disorders (that is: intrarenal hypertension, increased renal blood¯ow and transcapillary hydraulic pressure and enlarged glomerular surface area) may lead to structural alterations of GBM 37 and to elevated transglomerular¯ow of plasma proteins, 38 potentially increasing the transcapillary passage of albumin and IgG through the glomerular barrier. Likewise to the data reported in diabetes mellitus, 39 ± 41 the haemodynamic mechanism associated with glomerular hyper®ltration may therefore affect the loss of urinary proteins also in obese patients with CO. The selectivity index of these patients remained unchanged in spite of the pathological increase of AER and of the clearance of albumin. This evidence may suggest that glucagon can haemodynamically in¯uence both selective (low molecular weight) and non selective (high molecular weight) proteinuria, potentially increasing the risk to develop focal of diffuse glomerulosclerosis and kidney disease in central obesity. 39, 40 In agreement with previous studies, 14, 42 the increase of urinary excretion of a1 microglobulin, found in patients with CO, suggests that glucagon can negatively in¯uence the tubular reabsorption if proteins. Obesity with central body fat distribution might therefore represent a risk to develop proteinuria also with a tubular mechanism. 11, 43 Finally, as regard to the association between central obesity and proteinuria, a relevant feature of the present investigation concerns the lack of arterial blood pressure changes in obese patients with CO. Therefore, hyperinsulinaemia and MA could be associated with obesity independently of the occurrence of arterial hypertension. This may also indicate that the metabolic syndrome and proteinuria can precede the development of blood pressure alterations in CO and that the role of hyperinsulinaemia in the pathogenesis of hypertension in obesity might be due to other mechanisms than those reported in essential hypertension.
44,45
Conclusions
Our study demonstrates that increased serum glucagon concentration is a risk factor for the development of glomerular hyper®ltration in patients with central obesity. The correlation found between glucagon and GFR may also have a role in determining abnormal urinary protein loss and MA in these patients and could be potentially dangerous for vascular system by increasing the prevalence of CVD also in normotensive obese patients with central body fat distribution.
